The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Amicus Therapeutics Q3 EPS $(0.19) Misses $(0.18) Estimate, Sales $79.50M Miss $80.11M Estimate
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 13.64 percent increase over losses of $(0.22) per share
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
JP Morgan Upgrades Amicus Therapeutics to Overweight, Announces $16 Price Target
JP Morgan analyst Anupam Rama upgrades Amicus Therapeutics (NASDAQ:FOLD) from Neutral to Overweight and announces $16 price target.
SVB Leerink Maintains Market Perform on Amicus Therapeutics, Lowers Price Target to $12
SVB Leerink analyst Joseph Schwartz maintains Amicus Therapeutics (NASDAQ:FOLD) with a Market Perform and lowers the price target from $13 to $12.
Perceptive Advisors-Backed SPAC To Acquire Amicus’s Gene Therapy Business
Amicus Therapeutics Inc (NASDAQ:FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ:ARYD) and launch genetic medicine…
Why Are Amicus Therapeutics Shares Trading Higher Today?
The FDA has accepted for review Amicus Therapeutics Inc’s (NASDAQ:FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug…
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
